Live Breaking News & Updates on Vilhelm Magnus Laboratory At Oslo University Hospital

Share this article
Share this article
OSLO, Norway, May 10, 2021 /PRNewswire/  Hemispherian AS ( Hemispherian or the Company ), an innovative Norwegian preclinical pharmaceutical company focused on epigenetic therapeutics for the treatment of cancer, is delighted to announce the formation of its Clinical Advisory Board (CAB) by appointing as Chairman Dr Roger Stupp, Chief of Neuro-Oncology in the Department of Neurology and Paul C Bucy Professor of Neurological Surgery at Northwestern University Chicago and as members Dr. Michael Lim, Chairman of the Department of Neurosurgery at Stanford University; Dr. Monika Hegi Head of the Laboratory of Brain Tumour Biology and Genetics at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne; and Dr. Einar O. Vik-Mo, Head of the Surgical Neuro-Oncology section at Oslo University Hospital. The advisory board – comprising leading experts in their fields and having significant experience with novel technologies and their ....

Monika Hegi , Roger Stupp , Adam Robertson , Einar Vik Mo , Einaro Vik Mo , Zeno Albisser , Vilhelm Magnus Laboratory At Oslo University Hospital , Department Of Neurology , Oslo University Hospital , Centre Hospitalier Universitaire Vaudois , Department Of Neurosurgery At Stanford University , Clinical Advisory Board , Chairman Dr Roger Stupp , Paulc Bucy Professor , Neurological Surgery , Northwestern University Chicago , Michael Lim , Stanford University , Monika Hegi Head , Brain Tumour Biology , Surgical Neuro Oncology , Oslo University , Vilhelm Magnus Laboratory , Hemispherian Clinical Advisory Board , Chief Scientific , ரோஜர் ஸ்தூப்ப் ,